Table 4 Subgroup analysis of the included studies for outcome oligodendrocytes cell counts.

From: Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis

Subgroup Comparisons Effect estimate [95% CI] I2
Overall 55 2.09 [1.52, 2.66] 87%
Therapeutic regimen
therapeutically 49 2.10 [1.48, 2.71] 86%
Method
APC* 20 2.43 [1.48, 3.38] 88%
GST-pi 11 2.14 [0.91, 3.37] 83%
Nogo-A* 9 0.12 [āˆ’1.16, 1.36] 72%
CA2 5 3.64 [1.71, 5. 57] 83%
O4 3 4.86 [2.31, 7.41] 96%
Olig2/APC 3 2.51 [0.13, 4.89] 48%
MS model
Cuprizone*** 42 1.77 [1.12, 2.41] 86%
Lysolecithin*** 10 3.71 [2.27, 5.15] 91%
  1. The effect estimate was displayed by the standardized mean difference (SMD) and 95% confidence intervals (CIs). *Significant subgroup analysis between Nogo-A and APC (adjusted pā€‰=ā€‰0.049), and Cuprizone and Lysolecithin.